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ABSTRACT
Objective: The aim of this study is to design the optimal study comparing
endovascular revascularization and supervised exercise training for
patients with intermittent claudication and to demonstrate value of infor-
mation (VOI) analysis of patient-level data from an economic randomized
controlled trial to guide future research.
Methods: We applied a net beneﬁt framework to patient-level data on
costs and quality-of-life of a previous randomized controlled trial. VOI
analyses were performed using Monte Carlo simulation. We estimated the
total expected value of perfect information (total EVPI), the total expected
value of sample information (total EVSI), the partial expected value of
perfect information (partial EVPI), and the partial expected value of
sample information (partial EVSI). These VOI analyses identiﬁed the key
parameters and the optimal sample size of future study designs. Sensitivity
analyses were performed to explore the robustness of our assumptions
about the population to beneﬁt, the willingness-to-pay threshold, and the
study costs. The VOI analyses are demonstrated in statistical software (R)
and a spreadsheet (Excel) allowing other investigators to apply VOI analy-
sis to their patient-level data.
Results: The optimal study design for the treatment of intermittent clau-
dication involves a randomized controlled trial collecting data on the
quality-adjusted life expectancy and additional admission costs for 525
patients per treatment arm. The optimal sample size remained between
400 and 600 patients for a willingness-to-pay threshold between €30,000
and €100,000/quality-adjusted life-years, for even extreme assumptions
about the study costs, and for a range of 3 to 7 years that future patients
will beneﬁt from the results of the proposed study.
Conclusions: 1) The optimal study for patients with intermittent claudi-
cation collects data on two key parameters for 525 patients per trial arm;
and 2) we have shown that value of information analysis provides an
explicit framework to determine the optimal sample size and identify key
parameters for the design of future clinical trials.
Keywords: cost-effectiveness analysis, intermittent claudication, random-
ized controlled trial, value of information analysis.
Introduction
The adoption of new medical interventions depends nowadays
on evidence of cost-effectiveness in addition to evidence of effec-
tiveness. Consequently, economic data are increasingly collected
alongside clinical trials. We performed an economic trial to
compare endovascular revascularization and supervised exercise
training for patients with intermittent claudication [1]. Consid-
erable uncertainty about the optimal cost-effective medical inter-
vention remained after analysis of the trial. Given this
uncertainty, policymakers should address two separate decisions:
which intervention should be reimbursed and, is more
research—for example, a larger economic trial—justiﬁed [2]?
More quantitative research could be justiﬁed, because a decision
based on a trial with a ﬁnite sample size can be wrong: that is, the
intervention that is identiﬁed as optimal may not be the actual
optimal intervention. A future study could justify a change in
current care which may result in an improvement in quality-
adjusted life expectancy (QALE) of future patients and a decrease
in health-care costs. However, the actual beneﬁt of a future study
is uncertain. Before embarking on an expensive study, funding
agencies like to know the expected study cost. Money spent on
such a study cannot be spent otherwise, for example, to fund
another study or reimburse a new treatment. The cost of a study
is usually speciﬁed in a grant proposal. The expected beneﬁt of a
study typically receives little formal consideration. The challenge
of deciding whether more research is justiﬁed is to make the
cost–beneﬁt trade-off of future clinical research prior to perform-
ing it. More research is justiﬁed only if the expected beneﬁt
exceeds the cost of a proposed study.
Value of Information (VOI) analysis provides a framework to
guide the cost–beneﬁt trade-off of future cost-effectiveness
research prior to performing it. VOI analysis estimates the
expected beneﬁt of a future study using available evidence (e.g.,
a previous randomized controlled trial) about a decision. VOI
analysis can guide the design of a study that maximizes the
difference between the expected beneﬁt for future patients and
the expected cost of the study. This study is characterized by its
design (e.g., randomized or observational), the subset of sampled
parameters (e.g., quality-of-life only, or a selection of cost param-
eters), the sample size, and the associated study costs. Claxton
et al. have demonstrated the feasibility of VOI analysis to guide
the research priority setting of the National Health Service in the
United Kingdom [3].
Most published VOI analyses involve decision models [4].
Economic trials, however, are attractive for VOI analysis because
of their high internal validity. VOI analyses can be performed in
addition to conventional analyses of economic trials [5]. They
offer a sound alternative to signiﬁcance testing when deciding if
more research is needed. Moreover, VOI analysis provides a
framework for sample size calculation. Based on patient-level
data from an economic trial, VOI analysis can determine the
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optimal sample size of a future trial. The same methods can be
used when patient-level data from a previous trial are not avail-
able, using elicited estimates with uncertainty intervals of the
outcomes. Ideally, a VOI analysis is performed before and after a
clinical trial.
The ﬁrst objective of this article is to design the optimal study
comparing endovascular revascularization and supervised exer-
cise training for patients with intermittent claudication. The
second objective is to demonstrate VOI analysis of patient-level
data from an economic randomized controlled trial to guide
future research. In the following section, we brieﬂy discuss the
clinical problem, study design, and results of a previous trial of
patients with intermittent claudication. Next, we explain the
concepts and demonstrate the methods of the different VOI
analyses, focusing on the application of VOI analyses to patient-
level data from economic trials. The analyses are explained using
mathematical notation (conform Ades [6]) and step-by-step algo-
rithms, speciﬁcally for VOI analysis of patient-level data of
economic trials. We used Monte Carlo simulation to obtain the
VOI estimates. In the appendix, which can be found at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i2_
Hunink.asp, we present detailed instructions to perform VOI
analyses on patient-level data using a spreadsheet such as Excel
and statistical software such as R [7,8].
Treatment of Intermittent Claudication
Randomized Controlled Trial
Intermittent claudication is the mildest form of peripheral arte-
rial disease. Patients suffer from a limited walking distance due to
inadequate circulation of the legs. The treatment goal for inter-
mittent claudication is to improve health-related quality-of-life.
The general consensus is to treat these patients initially with
exercise training [9]. Endovascular revascularization seems an
attractive alternative with the advantage of immediate clinical
success [10]. However, the drawbacks of endovascular revascu-
larization include procedure-related morbidity and mortality as
well as increased costs [11,12].
Between September 2002 and September 2005, 150 patients
with intermittent claudication were randomly allocated to endo-
vascular revascularization or supervised exercise training [1].
During 12 months of follow-up, all medical and nonmedical costs
(11 cost parameters) were assessed from the societal perspective
and effects were measured with the EuroQol-5D questionnaire.
We transformed the EuroQol-5D values into utilities using the
Dutch scoring algorithm [13]. The improvement in quality-
adjusted life-years (QALYs) accumulated during the 12-month
follow-up period was then used as effect measure in the cost-
effectiveness analysis. We refer to the original article for more
details on the study design, analyses, and results [1]. The original
article presented results with adjustment for age and gender. Here,
we used unadjusted data for the VOI analyses. The improvement
in QALYs was higher in the revascularization group than in the
exercise group (mean difference 0.08; 95% conﬁdence interval
[CI] 0.04, 0.12). The total mean cumulative cost per patient was
also higher in the revascularization group than in the exercise
group (mean difference €4254; 95% CI €1648, €7734).
Cost-Effectiveness Analysis
We adopted the net beneﬁt approach to cost-effectiveness analy-
sis [14]. A decision between two strategies based on both costs
and effect can only be made if a trade-off is made between cost
and effect by putting a monetary value on health. We used a
societal willingness-to-pay threshold (WTP) of 80,000 euros per
QALY, as has recently been recommended by a Dutch govern-
mental institute [15]. Cost and effect (in this case, QALE) are
combined into a single outcome called net (monetary) beneﬁt: net
beneﬁt = WTP*effect - costs.
The net beneﬁt is expressed in euro. The mean net beneﬁt is
denoted by B. The difference in mean net beneﬁt between the two
interventions is the incremental mean net beneﬁt (IB). The uncer-
tainty interval for the IB was estimated parametrically and non-
parametrically [14]. The parametric intervals assume a normal
distribution of the IB, justiﬁed by the central limit theorem. To
check this assumption, we also performed nonparametrical boot-
strapping using 1 million bootstraps [16].
The revascularization group had a higher net beneﬁt (€4486
vs. €2316 per patient), but the difference in net beneﬁt was not
signiﬁcant (mean difference €2170; 95% CI €-2818, €6685).
Based on these results, we can conclude that revascularization
seems cost-effective, but considerable uncertainty remains.
Figure 1 presents the incremental net beneﬁt (IB) in euro with
95% uncertainty interval across a range of values for the WTP in
euro/QALY. The bootstrapping results showed that assuming
normal distributions was justiﬁed.
Total ExpectedValue of Perfect Information
(EVPI)—Eliminating Uncertainty
VOI analysis starts with estimating the total EVPI. It is the
expected beneﬁt per patient of a study with an inﬁnite sample
size, resulting in perfect information about all (total) uncertain
cost and effect parameters. Such a study would eliminate uncer-
tainty about the net beneﬁt of each intervention, but is of course
hypothetical. However, the total EVPI provides a ceiling level for
the expected cost of a future study; studies with a ﬁnite sample
size or studies that consider a subset of parameters all have a
smaller expected beneﬁt. Therefore, if the total EVPI does not
exceed the ﬁxed cost of research, more research is not justiﬁed.
More research is potentially justiﬁed if the total EVPI does
exceed the ﬁxed cost of research.
Total EVPI—Equations and Algorithm
The net beneﬁt B(a, q) of intervention a is a function of q, where
q stands for the set of all unknown distributional cost and effect
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Figure 1 The incremental net beneﬁt (IB) for the revascularization strategy in
euro with 95% uncertainty boundaries based on 1 million bootstraps of patient-
level net beneﬁts, across a range of values for the willingness-to-pay threshold
(WTP) in euro/QALY.
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parameters involved. If all uncertainty about the parameters
would be eliminated, the actual net beneﬁt of each intervention
would be known. The cost of not knowing the actual net beneﬁt
of each intervention is the cost of uncertainty or the opportunity
loss. It is deﬁned as the difference between the maximum actual
net beneﬁt, and the actual net beneﬁt of the supposedly optimal
intervention (a*):
opportunity loss *a actual actual= ( ) − ( )max , ,B a B aθ θ
We cannot calculate the opportunity loss, because we do not
know the actual parameter values qactual. However, the expected
opportunity loss is the expectation over the distribution of the
parameters of each intervention. The total EVPI equals the
expected opportunity loss:
total EVPI *a= ( ) − ( )[ ]E B a B aθ θ θmax , ,
To calculate the total EVPI, the parameters of each interven-
tion must be characterized by a probability distribution based on
the data of the initial trial. We can also use the probability
distribution of the mean net beneﬁt B(a,q) of each intervention.
Although the net beneﬁt may not be normally distributed in the
population, the uncertainty about the mean net beneﬁt typically is
(central limit theorem). As the distribution of the mean net beneﬁt,
we take N nμ σ0 0; pop( ), for each intervention; m0 is the esti-
mated mean net beneﬁt in the initial study, for each intervention;
spop is the estimated standard deviation in the initial study, for each
intervention; and n0 is the sample size in the initial study, for each
intervention. For simplicity, spop is treated as a known parameter,
based on the initial study [6], bj is a random value of the distribu-
tion of the mean net beneﬁt for intervention a. The algorithm for
the estimation of total EVPI involves the following steps:
1. draw a value bj for the net beneﬁt from N μ0;(
σopp.loss n0 ), for each intervention a
2. calculate the opportunity loss: maxa ja ja*b b−
3. repeat step 1 and 2 N times
4. the total EVPI is estimated by averaging over the opportu-
nity losses at step 2
The standard error of the mean opportunity loss σpop N( )
reﬂects how precisely the total EVPI was estimated. The process
of drawing a random value of each distribution (an iteration) is
sometimes referred to as the Monte Carlo simulation.
The Example—Total EVPI
Table 1 presents the results of the Monte Carlo simulation for 10
iterations. Each iteration consists of a random value of the dis-
tribution of the mean net beneﬁt of each intervention. For each
iteration, the opportunity loss is calculated. For example, exer-
cise was the optimal intervention in the ﬁrst iteration, and revas-
cularization was the optimal intervention based on the initial
trial results. Therefore, the opportunity loss of the ﬁrst iteration
equals €4372 - €3348 = €1024. Based on these 10 iterations
alone, the total EVPI is estimated by the mean opportunity loss of
€311.
A total EVPI of €249 per patient was found with 10 million
simulations in R. This means that after eliminating uncertainty,
we can expect an improvement in net monetary beneﬁt of €249
per patient. Endovascular revascularization was the optimal
intervention given the results of the initial trial, with an expected
net beneﬁt of €4486 per patient. With perfect information, the
expected net beneﬁt of the optimal intervention (which could be
endovascular revascularization or exercise training) is 4486 +
249 = €4735 per patient. The total EVPI per patient should be
extrapolated to the entire population that will beneﬁt from the
study results, to allow for comparison with the ﬁxed study cost.
Population EVPI and Study Cost
The expected beneﬁt of a study should include the beneﬁt of all
future patients from some predetermined perspective: single hos-
pital, health insurance agency, country, or worldwide. The
number of years (T) that future patients are expected to beneﬁt
from the results of a proposed study is difﬁcult to determine. It
depends on the improvement in technology and future evidence.
A sensitivity analysis can illustrate the importance of this uncer-
tainty. The expected beneﬁt to future patients is discounted by a
discount rate of typically 3% per year, that is, each year further
ahead a smaller beneﬁt is assigned on behalf of these patients
[17]. The population EVPI equals:
population EVPI total EVPI= ∗
+(
annualpopulation
discountrate1 )
=
∑ t
i
T
1
The study costs are typically estimated as ﬁxed cost (e.g., salary
of a PhD student) and variable cost per patient in the study [18].
The Example—Population EVPI and Study Cost
Because the initial trial was funded by a national governmental
agency, we used the national perspective for the annual population
to beneﬁt. This annual population was estimated at 10,000
patients for The Netherlands. We assumed patients would beneﬁt
from the results for 5 years and discounted these beneﬁts at 3% per
year. We found a discounted population to beneﬁt of about 46,000
patients and a population EVPI of 11 million euros. We estimated
the ﬁxed cost of an additional clinical study at 200,000 euros,
based on the cost of our previous study. Because the EVPI for the
population exceeds the expected costs of an additional study, it is
potentially justiﬁed to perform some sort of additional study.
Total ExpectedValue of Sample Information
(EVSI)—Reducing Uncertainty
The total EVSI is an estimate of the expected beneﬁt of studies
with a ﬁnite sample size, collecting information on all cost and
effect parameters. Instead of eliminating uncertainty, uncertainty
about the mean net beneﬁt of each intervention is only reduced.
With increasing sample size, the total EVSI will reach a ceiling
which equals the total EVPI, representing an inﬁnite sample size.
Total EVSI—Equations and Algorithm
A proposed study provides data about all cost and effect param-
eters of n patients for each intervention. The study will improve
Table 1 Total EVPI (in euro): 10 iterations of Monte Carlo simulation
Iteration Revascularization Exercise opportunity loss
1 3348 4372 1024
2 7997 3198 0
3 3129 3311 182
4 2267 2991 724
5 -466 711 1177
6 3716 2276 0
7 3179 2220 0
8 5204 962 0
9 3543 2435 0
10 7679 4489 0
Mean 311
EVPI, expected value of perfect information.
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the mean estimates of the parameter values, and consequently,
of the net beneﬁt of each intervention. Once we have observed
the actual study data D, the expected beneﬁt of treatment a*
is E B aθ θDactual *,( ). The best treatment then has the expected
beneﬁt max ,a DactualE B aθ θ( ). Thus, the current cost of uncertainty
about the actual study data D is the opportunity loss:
opportunity loss *a D Dactual actual= ( ) − ( )max , , .E B a E B aθ θθ θ
Because B is linear in q, this simpliﬁes to:
opportunity loss *a actual actual= ( )( ) − ( )( )max , , .B a E D B a E Dθ θ
We cannot calculate the opportunity loss, because we do not
know the actual data before performing the study. However, the
expected opportunity loss is the expectation over all possible
values of the new data. The total EVSI equals the expected
opportunity loss:
total EVSI *D a= ( )( ) − ( )( )[ ]E B a E D B a E Dmax , ,θ θ
Again, the analysis is simpliﬁed using the probability distribution
of the mean net beneﬁt N nμ σ0 pop; 0( ) of each intervention a
in the initial study. The data D of the proposed study is charac-
terized by the sample size n1, the sample mean net beneﬁt m1, and
the standard error σpop n1 for each intervention[6]. The m1 is
unknown, but can be sampled from the distribution of the actual
net beneﬁt N nμ σactual pop; 1( ) for each intervention. The mactual
is also unknown, but can be sampled from the distribution of the
mean net beneﬁt of the initial trial N nμ σ0 0; pop( ) for each
intervention. The algorithm for the estimation of the total EVSI
involves the following steps:
1. Choose a sample size n1 per intervention of the proposed
study.
2. Draw a value mactual,j from N nμ σ0 0; pop( ), for each
intervention.
3. Draw a value m1,j from N nμ σactual j pop;, 1( ), for each
intervention.
4. Calculate the posterior mean net beneﬁt for each
intervention a: b
n n
n n
j
a j
=
⋅ + ⋅
+
μ μ0 0 1 1
0 1
,
5. Calculate the opportunity loss: maxa ja ja*b b−
6. Repeat step 1 to 5 N times.
7. The total EVSI is estimated by averaging over the opportu-
nity losses at step 5.
Expected Net Beneﬁt of Sampling (ENBS)—
the Optimal Sample Size
The ENBS is deﬁned as the difference between the total EVSI and
the study cost. The optimal sample size is reached when the
ENBS reaches a maximum. At this maximum, the additional
beneﬁt of one more patient in the study equals the additional
study costs of one more patient in the study.
In addition to the ﬁxed cost and variable cost per patient, the
cost of clinical trials should also include the forgone net beneﬁt of
each patient that is randomized to an intervention that is sup-
posedly suboptimal. This amounts to the sample size of the
inferior arm of the trial times the difference in net beneﬁt based
on the previous trial.
The Example—Total EVSI, Study Costs, and ENBS
For a clinical trial collecting data on all parameters (total EVSI),
we estimated a ﬁxed cost of 200,000 euros and a variable cost of
€1000 per patient, both based on our previous (identical) study.
The difference in net beneﬁt between the revascularization and the
exercise group was €2170. The total cost in euro was therefore:
total study costs = + ∗ ∗ + ∗200 000 1 000 2 21701 1, , n n
Note that n1 is the sample size per study arm and not the total
sample size of the study. We used the same population to beneﬁt
about 46,000 patients (see section on total EVPI). Figure 2 pre-
sents the study cost, the total EVSI, and the ENBS as a function
of the sample size n1 per study arm. A maximum ENBS of €7.3
million is reached for a sample size of about 475 patients per
study arm. The study cost of this study would be 2.2 million, of
which 1.2 million is accounted for by the forgone net beneﬁt of
475 patients assigned to the supposedly suboptimal intervention
(supervised exercise training).
The ENBS of the proposed study is not the actual beneﬁt of the
study—which we will only learn after analyzing the results of the
study—but the expected beneﬁt, prior to performing the study.
The actual beneﬁt to an individual patient is zero if the new study
does not lead to a change in current care, because the patient’s
outcomes remain unchanged. The actual beneﬁt to an individual
patient is nonzero if the new study demonstrates that our initial
decision was suboptimal and current care is changed accordingly.
However, the proposed study will almost always improve the
precision of the outcomes and reduce the cost of uncertainty.
Partial EVPI—Eliminating Uncertainty of
Some Parameters
The partial EVPI estimates the expected beneﬁt of eliminating
uncertainty for individual parameters or subsets of parameters.
Typically, it is not justiﬁed to consider all parameters in a future
study: a few key parameters are the source of most decision
uncertainty. Eliminating uncertainty about the other parameters
has no additional expected beneﬁt or an expected beneﬁt that
does not justify the additional study costs.
Partial EVPI—Equations and Algorithm
For the estimation of partial EVPI, the parameters are divided
into two groups: the parameters-of-interest qI are considered in a
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Figure 2 Population EVSI, study costs and ENBS in million Euro for different
sample sizes per study arm.The proposed study collects data on all parameters
that were considered in the initial trial. The optimal sample size is about 500
patients per study arm with an ENBS of €7.2 million, and total study costs of
€2.3 million. Of the total study costs, €1.1 million is accounted for by the
forgone net beneﬁt of 500 patients assigned to the supposedly suboptimal
intervention (supervised exercise training).
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future study, the parameters-not-of-interest qC are not considered
in a future study. If all uncertainty about the parameters-of-
interest qI for each intervention would be eliminated, the actual
values of these parameters would be known. The current cost of
uncertainty of not knowing the actual values of the parameters-
of-interest θactualI of each intervention is called the opportunity
loss. It is deﬁned as the difference between the maximum
expected net beneﬁt given θactualI and the expected net beneﬁt
given θactualI of the supposedly optimal intervention (a*). Because
B(a, qC, qI) is linear in qC and qI, we get:
opportunity loss max
*,
a actual
I C
actual
I
ac
C= ( )( ) −B a, E
B a
θ θ θ
θ
θ,
tual
I C
actual
I
C, Eθ θ θ( )( )
We cannot calculate the opportunity loss, because we do not
know the actual values of the parameters-of-interest qI. However,
the expected opportunity loss is the expectation over all possible
values of the parameters-of-interest qI of each intervention. The
partial EVPI equals the expected opportunity loss:
partial EVPI max
*
I C
C
a
I C I
I C I
= ( )( ) −[
( )( )]
E B a, E
B a , E
θ θ
θ
θ θ θ
θ θ θ
,
,
Again, the analysis can be simpliﬁed by avoiding the distribu-
tions of individual parameters. Instead, we created distribu-
tions for the mean net beneﬁt of the parameters-of-interest
N nμ σ0 0I popI;( ) and the mean net beneﬁt of the parameters-
not-of-interest N nμ σ0 0C popC;( ), with correlation r, for each
intervention. The partial EVPI is estimated in the following algo-
rithm. The conditional mean net beneﬁt of the parameters-not-
of-interest qC is calculated in step 2 of the algorithm, using the
general equation for the conditional mean value of a bivariate
normal distribution. [19]
1. Draw a value bjI from N nμ σ0 0I popI;( ), for each
intervention.
2. Calculate the conditional mean net beneﬁt of qC, for each
intervention: b
b
j
C
0
C pop
C
j
I
0
I
pop
I
= +
∗ ∗ −[ ]μ σ ρ μ
σ
3. Calculate the mean net beneﬁt for each intervention:
b b bj jI jC= + .
4. Calculate the opportunity loss: maxa j ja*b ba − .
5. Repeat step 1 to 4 N times.
6. The partial EVPI is estimated by averaging over the oppor-
tunity losses at step 4.
Subsets of Parameters
In theory, we could estimate the partial EVPI for each subset of
parameters. To evaluate whether more research regarding each
subset is potentially justiﬁed, the partial EVPI is compared with
the subset-speciﬁc ﬁxed study costs. The number of required
analyses, however, would explode for even a small number of
parameters. In practice, investigators typically ﬁrst estimate the
partial EVPI for each individual parameter. Unfortunately, the
partial EVPI of individual parameters does not simply sum up to
the partial EVPI of a subset of parameters. Even a subset of
parameters with individual partial EVPIs of zero, together, may
have a nonzero partial EVPI. The subset of parameters with a
nonzero EVPI or substantial individual partial EVPI seems a
reasonable subset to consider for partial EVPI estimation. Other
relevant subsets are found by changing this subset. If the partial
EVPI of this subset is close to the total EVPI, we can remove
parameters with a small individual partial EVPI or a substantial-
associated increase in study costs (e.g., the quality-of-life param-
eter). If the partial EVPI is much smaller than the total EVPI, we
can add parameters with small additional study costs (e.g., a cost
parameter that can be collected from administrative records).
The Example—Partial EVPI
Table 2 presents the partial EVPI of each individual parameter
with 10 million simulations in R. Of the 12 parameters, only four
had a nonzero individual partial EVPI. Together, these four
parameters had a partial EVPI of €248 per patient; almost the
same as the total EVPI of 249. The partial EVPI of the three
parameters with the highest individual EVPI was also €248 per
patient. The two parameters with the highest individual partial
EVPI together had a partial EVPI of 244. For the subsets with
two and three parameters, we identiﬁed the optimal sample size
in the next section. The partial EVPI of the subset of eight
parameters with an individual partial EVPI of zero was still zero.
Obtaining more information on these parameters is not justiﬁed,
even for very small additional study costs.
Five cost parameters had a similar expected value, ranging
from 437 euros to 742 euros per patient: the cost of material,
personnel, overhead, treatment, and productivity loss. The
partial EVPI of treatment cost was 6 euros per patient. The
partial EVPI of the other four parameters together was zero.
These results demonstrate that simply selecting the parameters
with the highest expected value, or the parameters that differed
most between treatments, is not a good alternative for partial
VOI analysis.
Partial EVSI—Reducing Uncertainty of
Some Parameters
The partial EVSI is an estimate of the expected beneﬁt of studies
with a ﬁnite sample size, collecting information on a subset of
parameters. With increasing sample size, the partial EVSI will
reach a ceiling: the partial EVPI, representing an inﬁnite sample
size.
Partial EVSI—Equations and Algorithm
A future study provides data D about the parameters-of-interest
qI of n patients for each intervention. The study will improve the
mean estimates of the parameters-of-interest qI, and conse-
quently, of the net beneﬁt of each intervention. The current cost
of not knowing the actual study data Dactual is called the oppor-
tunity loss. It is calculated as the difference between the
maximum expected net beneﬁt given Dactual, and the expected
net beneﬁt given Dactual, of the supposedly optimal intervention
(a*):
Table 2 Partial EVPIs
Individual parameters
Partial EVPI
in euro
QALYs 104
Additional admission costs 65
Additional treatment costs 6
Additional imaging costs 0.007
Subsets of parameters
All 12 parameters = total EVPI 249
All 4 with nonzero individual pEVPI 248
All 3 with individual pEVPI > 1 248
All 2 with individual pEVPI > 10 244
All 8 with zero individual pEVPI 0
All 11 cost parameters 69
EVPI, expected value of perfect information; QALYs, quality-adjusted life-years.
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opportunity
*
a
I
actual
C I
actualI C= ( ) ( )( )( ) −max ,B a, E D E D
B a
θ θθ θ θ
, I CI actual C I actualE D E Dθ θθ θ θ( ) ( )( )( ),
We cannot calculate the opportunity loss, because we do not
know the actual data before performing the study. However, the
expected opportunity loss is the expectation over all possible
values of the new data. The partial EVSI equals the expected
opportunity loss:
partial
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Analogous to estimating the partial EVPI, we used the observed
distributions for the mean net beneﬁt of the parameters-of-
interest N nμ σ0 0I popI;( ) and the mean net beneﬁt of the
parameters-not-of-interest N nμ σ0 0C popC;( ), with correlation r,
for each intervention. The data of the proposed study is charac-
terized by the mean net beneﬁt of the parameters-of-interest μ1I
and the standard error σpopI n1 for each intervention[6]. The
μ1I is unknown, but can be sampled from the distribution
of the actual net beneﬁt of the parameters-of-interest
N nμ σactualI popI; 1( ), for each intervention. The μactualI is also
unknown, but can be sampled from the distribution of the mean
net beneﬁt of the parameters-of-interest observed in the initial
study N nμ σ0 0I popI;( ), for each intervention. The partial EVSI
is estimated in the following algorithm.
1. Choose a sample size n1 per intervention of the proposed
study.
2. Draw a value μactual jI , from N nμ σ0 0I popI;( ), for each
intervention.
3. Draw a value μ1 jI , from N nμ σactual jI popI;, 1( ), for each
intervention.
4. Calculate the posterior mean net beneﬁt of q1, for
each intervention: b
n n
n n
j
I 0
I
1 j
I
=
∗ + ∗
+
μ μ0 1
0 1
, .
5. Calculate the conditional mean net beneﬁt of qC, for each
intervention: [19] b
b
j
C
0
C pop
C
j
I
0
I
pop
I
= +
∗ ∗ −[ ]μ σ ρ μ
σ
.
6. Calculate the mean net beneﬁt for each intervention:
b b bj jI jC= + .
7. Calculate the opportunity loss: maxa ja ja*b b− .
8. Repeat step 1 to 7 N times.
9. The partial EVSI is estimated by averaging over the oppor-
tunity losses at step 7.
Although the proposed data collection sampled only the
parameters-of-interest, the net beneﬁt of each intervention is
estimated using all available data of all parameters (step 6). The
net beneﬁt of the parameters-of-interest is estimated using data
from both the initial study and the proposed data collection (step
4). The net beneﬁt of the parameters-not-of-interest is estimated
using data from the initial study only, unless a correlation (r)
exists with the parameters-of-interest (step 5).
The Example—Partial EVSI, Study Costs, and ENBS
We estimated the partial EVSI, for various sample sizes, for two
subsets of parameters that were identiﬁed with the analysis of
partial EVPI. These subsets include, respectively, three and two
parameters with the highest individual partial EVPI. We esti-
mated that collecting information on the QALE represents 50%
of the ﬁxed and variable study costs: 100,000 euros and 500
euros per patient. Also, collecting hospital admission costs
implies searching administrative records: we estimated an
increase in study costs of 10,000 euros plus 50 euros per patient.
Also, collecting the additional treatment costs requires more
resources: we estimated an increase in study costs of 20,000
euros plus 100 euros per patient. We used the same population to
beneﬁt of about 46,000 patients (see section on total EVPI).
For the subset of two parameters, the optimal sample size was
525 patients per study arm and the ENBS was 7.6 million euros.
For the subset of three parameters, we found an optimal sample
size of 500 patients per study arm and an ENBS of also 7.6
million euros. Although the expected beneﬁt of the studies is
equal, we prefer the former study because of lower study costs.
This optimal study design obtains data on the QALY and addi-
tional admission costs for 525 patients per study arm. The
required study costs are 690,000 euros. Assigning 525 patients to
the supposedly suboptimal arm has an associated cost of 1.1
million euros. To estimate study costs, we assumed a randomized
controlled trial as optimal design to reassure validity of the
results. Figure 3 presents several sensitivity analyses for the WTP
threshold, the population to beneﬁt, and the study costs.
Alternative Methods
We performed VOI analysis assuming a normal distribution of
the mean net beneﬁt of each intervention, based on the central
limit theorem. The total EVPI can also be estimated using boot-
strapping techniques, which do not rely on the normality
assumption.[16] With 1 million bootstraps in R, we found a total
EVPI of €264 per patient; very close to the €249 that we found,
assuming a normal distribution of the mean net beneﬁts. Unfor-
tunately, it is not obvious how bootstrapping should be imple-
mented to estimate partial value of information and sample
information. Other nonparametric methods for VOI analysis are
being developed [6].
We assessed the total EVPI using unadjusted estimates for the
mean net beneﬁt of each intervention. As another alternative, we
used regression analysis in the net beneﬁt framework to obtain
estimates of the mean net beneﬁt adjusted for potential imbal-
ances of baseline characteristics between the treatment groups.
The resulting total EVPI was €119 per patient. The adjusted
outcomes probably underestimate the VOI; the unadjusted out-
comes may overestimate the VOI. The regression analysis
ambiguously decomposes the total variance into components
attributable to patient heterogeneity and uncertainty. Both uncer-
tainty and estimates of the VOI will decrease when more varia-
tion is attributed to heterogeneity.
Both Claxton and Willan estimated the total EVPI and total
EVSI using closed form (analytical) methods that do not rely on
simulation [17,18]. Using closed form solutions, Claxton also
considered the VOI of trial designs assigning unequal sample
sizes to each intervention [20]. Although closed form solutions
for estimating the partial EVPI and partial EVSI are not available
in the literature, it should be possible to derive such solutions.
The advantages of closed form solutions are exact outcomes and
negligible calculation time. Simulation, however, also has several
advantages as compared with closed form solutions. The simu-
lations that we applied to our example can be easily modiﬁed to
accommodate more than two comparators, prior distributions
other than normal and nonlinear functions of the parameters.
Moreover, simulation has educational appeal; by following the
steps of the simulation, the reader understands how it works.
Discussion
With VOI analysis, we found that more research is justiﬁed
regarding the choice between endovascular revascularization and
supervised exercise training for patients with intermittent clau-
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dication. The optimal study design for a future study involves a
randomized controlled trial collecting data on the QALE and
additional admission costs for 525 patients per treatment arm.
The outcome of this trial could justify a change in current care.
As a result, future patients may beneﬁt from an increase in
quality-of-life, or cost savings may allow the health care system
to reimburse other (unrelated) beneﬁcial interventions. Although
we do not know the actual beneﬁt of the proposed study, the VOI
analysis estimated an ENBS of 7.6 million euros for The Neth-
erlands, using the results of a previous trial. The study costs of
690,000 euros were accounted for in this estimate. No other
study design had a higher ENBS. Sensitivity analyses demon-
strated that the optimal sample size was fairly stable. It remained
between 400 and 600 patients for a WTP threshold between
€30,000 and €100,000/QALY, for extreme assumptions about
the study costs, and for a range of 3 to 7 years that future patients
will beneﬁt from the results of the proposed study. These results
were used for a recent grant proposal. The €7.6 million of the
proposed study can be compared with the ENBS of other (unre-
lated) study proposals. The ENBS can guide a funding agency to
set priorities if the research budget is limited: study proposals
with a higher ENBS should be reimbursed ﬁrst. However,
funding is justiﬁed for any study proposal with an ENBS exceed-
ing zero.
An important assumption of VOI analysis is that health-care
costs and research costs are ultimately paid for from the same
resources, which is largely true for The Netherlands. The appro-
priate perspective of the VOI analysis regarding the population
to beneﬁt from the results of a study proposal is not obvious.
Because the initial trial of our example was funded by a national
governmental agency, we used the national perspective. For a
European Union or worldwide perspective, the population to
beneﬁt would increase at least 20-fold, resulting in an optimal
sample size of several thousand patients. The period that patients
will beneﬁt from the proposed data collection is also uncertain
because of uncertainty about future technological improvements
and evidence from future studies. These ambiguities, however,
are not drawbacks of VOI analysis in itself, but inherent to
setting research priorities.
We demonstrated VOI analysis using patient-level data from
a single clinical trial. We may have overestimated uncertainty and
the value of information, because we did not consider all avail-
able evidence pertaining to the decision. A decision model can
bring together evidence from various sources and also extrapo-
late costs and effects beyond the follow-up period in the initial
trial. However, decision models also have several drawbacks.
Many assumptions are required when building decision models,
to the extent that for the same research question, different models
report diverging results [21]. As a consequence, the validity of
models is often challenged. Moreover, building models is very
time-consuming and requires expertise on both the clinical
subject matter as well as the methodology of decision modeling.
On the other hand, this investment of time may be worthwhile,
because VOI analyses of such a decision model could conclude
a
b
c

Figure 3 (a) Sensitivity analysis for the willingness-to-pay threshold and the
study costs.The proposed study collects information on the quality-adjusted life
expectancy (QALE) and the additional admission costs. The population to
beneﬁt is about 46,000 patients.The study costs estimates are: ﬁxed 10,000 and
variable 100 euro (€); ﬁxed 110,000 and variable 550 (€€: base-case); and ﬁxed
500,000 and variable 2000 (€€€).The X presents the base-case willingness-to-
pay threshold and study costs. (b) Sensitivity analysis for the population to
beneﬁt and the study costs. The proposed study collects information on the
QALE and the additional admission costs. The willingness-to-pay threshold is
80,000 euro/quality-adjusted life-years (QALY).The study costs estimates are:
ﬁxed 10,000 and variable 100 euro (€); ﬁxed 110,000 and variable 550 (€€:
base-case); and ﬁxed 500,000 and variable 2000 (€€€). The X presents the
base-case population to beneﬁt of about 46,000 patients. (c) Sensitivity analysis
for the population to beneﬁt and the willingness-to-pay threshold. The pro-
posed study collects information on the QALE and the additional admission
costs.The study costs are €110,000 for ﬁxed costs and €550 for the costs per
patient.The X presents the base-case population to beneﬁt.
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that more research is not justiﬁed. Finally, most decision models
are nonlinear and require extremely computer-intensive nested
VOI analyses [6]. VOI analysis of patient-level data can avoid
these nested analyses because the net beneﬁt is a linear function
of the cost and effect parameters. Clinical trials remain attractive
because of their high internal validity and timeliness [5]. For
many clinical decisions, a trial constitutes the best available
evidence, not only to decide what medical intervention should be
adopted, but also to address the question whether more research
is needed. VOI analysis of trials is aimed at replacing the use of
signiﬁcance testing to determine whether more research is justi-
ﬁed; it is not aimed at replacing decision models to guide further
research. Advocates for economic trials will emphasize their
internal validity, although advocates for models stress their con-
sideration of all available evidence. Whether a decision model is
required to guide future research will depend on the methods and
results of the initial study, as well as the importance of evidence
from other sources.
A limitation of trials as compared with models is that clinical
trials rarely have a lifetime follow-up of costs and effects. This is
not only a drawback of VOI analysis of trials, but inherent to any
analysis of a trial. Sometimes a model is used to extrapolate
the trial data beyond the follow-up period [22]. The follow-up
of our initial trial was only 12 months. However, both
interventions—endovascular revascularization and exercise
training—give only temporary relief of symptoms. Improvement
of quality-of-life in our study was more immediate after revas-
cularization, but at 12 months, no difference was detected in
quality-of-life. Like most interventions in surgery, the costs are
largely incurred up front. The base case analysis of a model based
on our trial data would assume that no difference in costs and
effects is anticipated beyond the follow-up of the trial.
We recommend a randomized controlled trial as the optimal
design for the future study. Alternatively, an observational study
could collect data on quality-of-life and admission costs. The
drawback of a nonrandomized design is that it is more difﬁcult to
avoid the differences in (known and unknown) baseline patient
characteristics (i.e., confounders) that are responsible for differ-
ences between the outcomes of interventions. Moreover, a ran-
domized design is not necessarily associated with additional
study costs.
Few applications of VOI analysis to guide the design of
clinical trials have been published. In 2005, a guidance document
for designing and analyzing cost-effectiveness analyses conducted
as part of clinical trials did not mention VOI analysis.[5]
However, the philosophy of a formal cost–beneﬁt trade-off prior
to experimental studies is not new. VOI analysis was introduced
by Grundy [23] in the late ﬁfties and developed by Raiffa and
Schlaifer [24]. Howard noted in 1966 that: “Placing a value on
the reduction of uncertainty is the ﬁrst step in experimental
design, for only when we know what it is worth to reduce
uncertainty do we have a basis for allocating our resources in
experimentation designed to reduce the uncertainty.” In 1989,
Detsky evaluated the effect of design choices made in the plan-
ning stages of a clinical trial on the costs and beneﬁts derived
from conducting the trial [25,26]. Claxton introduced VOI
analysis to the clinical audience of the Lancet [2]. Moreover, he
demonstrated VOI analysis to estimate the optimal sample size of
a trial using hypothetical data [17]. More recently, Willan
applied VOI analysis to estimate the optimal sample size of a trial
using patient-level data from a previous trial [27]. Both studies
used closed form solutions that are not available in the literature
for partial value of information analyses. Further research could
ﬁnd out closed form solutions for some partial value of informa-
tion analyses.
Although the VOI analyses are relatively complex and tech-
nical, the fundamental ideas of VOI analysis is rather straight-
forward and may appear familiar to clinicians. A clear analogy
exists between the Bayesian framework for VOI analysis and
Bayesian diagnostic reasoning. A future trial can change the
probability that an intervention is optimal, just as a diagnostic
test can change the probability that a patient has a certain
disease. Both a trial and a diagnostic test are costly and require a
cost–beneﬁt trade-off. The probability and the consequences of
implementing a suboptimal intervention or misdiagnosing a
patient determine whether more research or a diagnostic test is
justiﬁed.
Clinical trials often show no statistically signiﬁcant difference
between the treatments compared. We demonstrated that VOI
analysis allows for a formal comparison of the expected beneﬁt
and the cost of a proposed study, before concluding whether or
not more research is justiﬁed. Two erroneous conclusions are
common about the need for more research when no signiﬁcant
difference is found. Some authors conclude that the decision has
been settled: the interventions are assumed to be equivalent and
more research is not needed. It has long been demonstrated,
however, that a difference is often not found because the study
was underpowered to detect even a large difference [28]. In a
famous quote, Altman warned that: “Absence of evidence is not
evidence of absence” [29]. Other authors conclude the exact
opposite—more research is needed—when no signiﬁcant differ-
ence is found. They seem to reason that there must be a difference
and because it was not found with the current study, another
(larger) study is needed. Phillips pointed out that the conclusion
“more research is needed” requires some assessment of the
expected beneﬁt for future patients that would come from more
research in comparison to the cost of research (e.g., VOI analy-
sis). He observed that studies in health care typically conclude
that “more research is needed” without such an assessment [30].
If more research is justiﬁed, the investigators should decide on
a sample size. We demonstrated VOI analysis as an explicit
framework to perform sample size calculations. Classical sample
size calculations are based on arbitrary values for the minimal
clinically signiﬁcant difference in treatment effect, a type I
error (typically a = 0.05), and a type II error (typically
b = 1 - power = 0.2). In practice, the equation is often back-
solved after substituting in a sample size that primarily reﬂects
feasibility and cost. VOI analysis considers the actual harm to
future patients of making a type I error (i.e., rejecting the null-
hypothesis when it is true) and a type II error (not rejecting the
null-hypothesis when it is false). The optimal sample size is
estimated by considering the marginal cost and beneﬁts of sam-
pling patients. Moreover, VOI analysis can conclude that more
research is not justiﬁed [31]. We recommend performing VOI
analyses before and after an economic trial.
Source of ﬁnancial support: Financial support for this study was provided
entirely by a grant from ZonMW (The Netherlands organization for
health research and development), a government agency. The funding
agreement ensured the authors’ independence in writing and publishing
the report.
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